Q1 EPS Forecast for Eton Pharmaceuticals Boosted by Analyst

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) – Equities research analysts at B. Riley raised their Q1 2025 earnings per share (EPS) estimates for Eton Pharmaceuticals in a research note issued to investors on Wednesday, March 19th. B. Riley analyst M. El-Saadi now expects that the company will post earnings of $0.06 per share for the quarter, up from their previous forecast of $0.03. B. Riley currently has a “Buy” rating and a $24.00 price target on the stock. The consensus estimate for Eton Pharmaceuticals’ current full-year earnings is ($0.14) per share. B. Riley also issued estimates for Eton Pharmaceuticals’ Q2 2025 earnings at $0.00 EPS.

ETON has been the topic of a number of other research reports. HC Wainwright restated a “buy” rating and issued a $33.00 target price on shares of Eton Pharmaceuticals in a research note on Wednesday. Craig Hallum lifted their price target on Eton Pharmaceuticals from $23.00 to $26.00 and gave the stock a “buy” rating in a report on Wednesday.

Eton Pharmaceuticals Stock Performance

Eton Pharmaceuticals stock opened at $14.78 on Thursday. Eton Pharmaceuticals has a fifty-two week low of $3.03 and a fifty-two week high of $18.41. The firm’s 50-day simple moving average is $15.56 and its 200 day simple moving average is $11.47. The stock has a market cap of $385.03 million, a PE ratio of -67.18 and a beta of 1.37.

Eton Pharmaceuticals (NASDAQ:ETON) last posted its quarterly earnings data on Tuesday, March 18th. The company reported ($0.02) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.02). The firm had revenue of $11.65 million for the quarter, compared to the consensus estimate of $10.53 million. Eton Pharmaceuticals had a negative net margin of 15.81% and a negative return on equity of 36.29%.

Institutional Trading of Eton Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in ETON. Tower Research Capital LLC TRC bought a new position in shares of Eton Pharmaceuticals during the 4th quarter valued at approximately $86,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in Eton Pharmaceuticals in the third quarter valued at approximately $54,000. Jefferies Financial Group Inc. bought a new position in Eton Pharmaceuticals during the fourth quarter valued at $133,000. Raymond James Financial Inc. purchased a new stake in Eton Pharmaceuticals in the fourth quarter worth $147,000. Finally, Bank of America Corp DE raised its stake in shares of Eton Pharmaceuticals by 5,422.4% in the fourth quarter. Bank of America Corp DE now owns 11,100 shares of the company’s stock valued at $148,000 after buying an additional 10,899 shares during the period. Hedge funds and other institutional investors own 27.86% of the company’s stock.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.